The estrogen patch: how it works and how it compares

An estrogen patch is a thin adhesive film that releases estradiol, the same estrogen your ovaries produce, through the skin into the bloodstream at a steady rate. Because it skips the first pass through the liver that oral estrogen undergoes, it does not raise clotting factors the way pills do, and large observational studies show no increase in blood clots. It relieves hot flashes, night sweats, and vaginal symptoms as effectively as oral estrogen and is changed once or twice a week.

How the patch works

Swallowed estrogen is absorbed from the gut and goes straight to the liver, where high concentrations stimulate production of clotting proteins before the hormone reaches the rest of the body. ACOG’s committee opinion on route of administration describes this “first-pass” effect as the likely reason oral estrogen is linked to blood clots, and notes that transdermal estradiol has little or no effect on those clotting proteins.

A patch delivers estradiol directly into the small blood vessels under the skin. Blood levels stay fairly constant between changes rather than peaking after each pill.

What it is approved for

FDA-approved estradiol patches are indicated for moderate to severe hot flashes and night sweats, moderate to severe vaginal atrophy symptoms, low estrogen from ovarian failure or surgery, and prevention of postmenopausal osteoporosis. For vaginal symptoms alone, the label advises considering low-dose vaginal products first.

Doses and how to use it

Twice-weekly patches come in five strengths. From the label of one widely used product:

Dose (mg estradiol per day)	Typical use
0.025	Starting dose for osteoporosis prevention; low-dose symptom control
0.0375	Recommended starting dose for hot flashes
0.05	Common maintenance dose
0.075	Higher dose if symptoms persist
0.1	Highest strength

The label says to start at 0.0375 mg per day for hot flashes, adjust by response, and reassess periodically. Other products are changed once a week.

Application, per the label: place on clean, dry skin of the lower abdomen or buttocks; never on the breasts; avoid the waistline, where clothing can rub it off; apply immediately after opening and press with the palm for about 10 seconds, especially around the edges; rotate sites with at least a week before reusing one. If you are switching from an oral estrogen, start the patch a week after the last pill, or sooner if symptoms return.

If you have a uterus, you also need a progestogen. Options are oral micronized progesterone (see our guide), a synthetic progestin pill, a combination patch containing both hormones, or a levonorgestrel IUD used off-label.

Patch versus pill: effectiveness

Equal. The Menopause Society’s 2022 statement cites a meta-analysis finding no significant difference between transdermal and oral combined therapy for hot flashes. Dose, not route, determines relief, and both routes protect bone.

Patch versus pill: blood clots and stroke

This is where the routes differ. No randomized trial has compared them with clot outcomes, but the observational evidence points the same way.

Study	Oral estrogen	Transdermal estradiol
French ESTHER case-control study, cited by ACOG	Odds of clot 4.2 vs non-users	0.9 (no increase)
UK QResearch and CPRD, 80,396 clot cases	Odds 1.58 overall; 2.10 for conjugated estrogen plus medroxyprogesterone	0.93 (no increase)
Meta-analysis of 15 observational studies	Oral vs transdermal: 1.63 for clots, 2.09 for deep vein thrombosis, 1.24 for stroke (one study), no difference for heart attack	Reference group

Absolute risk matters here. ACOG cites a background clot rate of about 54 per 100,000 women per year in the 40s, rising to 62 to 122 per 100,000 in the 50s. A 1.6-fold increase on oral therapy adds a few dozen cases per 100,000 women per year; the patch appears to add none. For a woman with extra clot risk, such as obesity, a prior clot, or a clotting mutation, that difference is the reason The Menopause Society says transdermal estradiol is generally preferred.

The Menopause Society also notes, on observational evidence, that lower estrogen doses may carry less stroke risk, and that micronized progesterone may be less clot-promoting than synthetic progestins. The meta-analysis authors rated their own evidence as warranting low confidence, which is honest: the patch has not been proven safer in a trial, but nothing in the data suggests it is riskier.

Other differences

• Libido and sex hormones. Oral estrogen raises sex hormone-binding globulin, which lowers free testosterone. The Menopause Society suggests transdermal estrogen may be preferable if low libido is a concern.
• Skin irritation. Redness or itching at the site occurred in about 3 percent or fewer of trial participants for the product whose label we reviewed. Rotating sites and avoiding lotion on the area help.
• Adhesion. Patches can lift with heat, sweat, or swimming. Some products adhere better than others; switching is reasonable.
• Convenience. Two patch changes a week versus a daily pill. Combination patches also remove the separate progestogen.

Side effects

The most common adverse reactions in the label, reported by 10 percent or more, are headache, breast tenderness, nasal and sinus congestion, upper respiratory infection, back pain, depression, and irregular vaginal bleeding or spotting. Breast tenderness tends to be dose-related and often eases with time or a lower dose. Spotting in the first months is common with any regimen; bleeding that continues past 6 months should be evaluated.

Note that the label we link, revised in late 2023, still carries the older boxed warning. The FDA asked manufacturers in November 2025 to remove cardiovascular disease, breast cancer, and dementia from that box and began approving revised labels in 2026, so the insert you receive may be either version for a while.

Supply and cost

Interest in hormone therapy rose after the FDA’s 2025 action. In a September 2026 update, the FDA said some patients were having trouble finding their usual estradiol patch, that supply had nearly doubled over the previous year across six manufacturers, and that patches remain available. It advises asking your pharmacist to locate a substitutable FDA-approved estradiol patch and contacting your clinician if a different product or dose form is needed.

Because several manufacturers make estradiol patches, what you pay depends on your plan’s formulary and tier. Ask the pharmacy to check both your prescribed product and interchangeable alternatives before you fill.

Who the patch suits

The patch is a reasonable first choice for most women and the preferred choice when clot risk is elevated, including with obesity or a known clotting disorder, and as women age on continued therapy, when The Menopause Society says a nonoral route becomes increasingly important.

It is not an option for women with contraindications to any systemic estrogen. The label lists undiagnosed abnormal genital bleeding; breast cancer or a history of it; other estrogen-dependent cancers; active or prior deep vein thrombosis or pulmonary embolism; active or prior arterial events such as stroke or heart attack; liver disease; and known clotting disorders such as protein C, protein S, or antithrombin deficiency.

Questions to ask

• Why do you suggest this route for me?
• Which strength are we starting with, and how will we adjust?
• Which progestogen goes with it, and on what schedule?
• What should I do if the patch is out of stock?
• When will we review how it is working?

If you want to compare your options before the visit, our symptom check produces a summary you can bring, and our OB-GYN directory lists clinicians near you.